PPV-06 is under clinical development by Peptinov and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PPV-06’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PPV-06 overview
PPV-06 is under development for the treatment of knee osteoarthritis and inflammation (other indications). The vaccine candidate is administered through subcutaneous route. The vaccine candidate constitutes peptides derived from IL-6 (interleukin-6) coupled with a carrier protein. It is developed based on drug design platform which utilizes in-silico drug design approach.
It was also under development for the treatment of systemic sclerosis.
Peptinov overview
Peptinov is a biotechnology company that develops peptide-based immunotherapies targeting self-proteins, for the treatment of chronic inflammatory diseases and cancers. Peptinov’s pipeline product includes PPV-06 lead immunotherapy targets IL-6, a central pro-inflammatory cytokine whose overproduction includes the pathogenesis of several chronic diseases such as rheumatoid arthritis, osteoarthritis, systemic sclerosis, or Horton’s disease. The company’s product is being evaluated in regulatory pre-clinical development. Its drug design platform is used to develop small molecule inhibitors of cytokines based on an in silico drug design approach. The company works in collaboration with hospitals, academic institutions and specialists. Peptinov is headquartered in Paris, Ile-de-France, France.
For a complete picture of PPV-06’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
